Verastem VSTM
NASDAQ VSTM
$7.70 -0.20 (-2.53%)
At close: Oct 2, 2026 · 4:00 PM EDT

Verastem (VSTM) Gains from Sales and Divestitures (2018)

Updated

Verastem (VSTM) posted Gains from Sales and Divestitures of $79,000 for FY2018.

Analysis

Verastem (VSTM) Gains from Sales and Divestitures (2018) Analysis & Trends

  • The FY2018 figure stands as the lowest annual Gains from Sales and Divestitures since FY2015.
  • Business Quant data shows VSTM's Gains from Sales and Divestitures at -$46,000 in FY2015 and -$4,000 in FY2014.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Verastem 696.71 Mn 53.34 Mn 36.32 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2018 46,000.00
Mar 31, 2018 33,000.00
API Access

Verastem Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VSTM&period=max&api_key=YOUR_API_KEY